Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer

Gynecologic Oncology

Volumn 72, Issue 1, 1999, Pages 76-81

  Gadducci, Angiolo ^a   Ferdeghini, Marco ^a   Buttitta, Fiamma ^a   Cosio, Stefania ^a   Fanucchi, Antonio ^a   Annicchiarico, Carmela ^a   Gagetti, Ornella ^a   Bevilacqua, Generoso ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM TUMOR; FEMALE; GENETIC CODE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

EID: 0032954463     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5101     Document Type: Article

References (45)

1. Lane DP: p53, guardian of the genome. Nature 358:15-16, 1992
2. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
3. Lane DP: A death in the life of p53. Cancer 362:786-787, 1993
4. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546, 1992
5. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 18:1318-1327, 1993
6. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523-526, 1992
7. Caron de Fromentel C, Soussi T: Tp53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4:1-15, 1992
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49-53, 1991
9. Chang F, Syrjanen S, Syrjanen K: Implications of the p53 tumor suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022, 1995
10. Hall PA, Lane DP: p53 in tumour pathology: can we trust immunohistochemistry? revisited. J Pathol 172:1-4, 1994
11. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
12. Labrecque S, Naor N, Thomson D, Matlashewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53:3468-3471, 1993
13. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, Caron de Fromentel C, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, Le Duc A, Peyrat JP, Janin N, Bressac B, Soussi T: Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53:5872-5876, 1993
14. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T: Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69:809-816, 1994
15. Houbiers JGA, van der Burg SH, van de Watering LMG, Tollenaar RAEM, Brand A, van de Velde CJH, Melief CJM: Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72:637-641, 1995
16. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403-408, 1982
17. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380-6384, 1992
18. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168-4174, 1992
19. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480-487, 1994
20. Preudhomme C, Lubin R, Lepelley P, Vanrumbeke M, Fenaux P: Detection of serum anti-p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 8:1589-1591, 1994
21. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ: The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69:1115-1119, 1994
22. Wild CP, Ridanpaa M, Anttila S, Lubin R, Soussi T, Husgafvel-Pursiainen K, Vainio H: p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 64:176-181, 1995
23. Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, Hirsch A, Soussi T: Serum p53 antibodies as early markers of lung cancer. Natl Med 1:701-702, 1995
24. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T: Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345:621-622, 1995
25. Green JA, Robertson LJ, Campbell IR, Jenkins J: Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev 19:151-155, 1995
26. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer 77:2146-2152, 1996
27. Gadducci A, Ferdeghini M, Buttitta F, Fanucchi A, Annicchiarico C, Prontera C, Bevilacqua G, Genazzani AR: Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. Anticancer Res 16:3519-3524, 1996
28. Maggino T, Gadducci A, Romagnolo C, Fanucchi A, Fioretti P: Times and sites of relapses after negative second-look in advanced epithelial ovarian cancer. Eur J Surg Oncol 20:146-150, 1994
29. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R: Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 58:42-47, 1995
30. Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89:3439-3442, 1992
31. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxin and hyperthermia. Biochem Pharmacol 40:2353-2362, 1990
32. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
33. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
34. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562, 1996
35. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou G, Benard J: Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 68:67-74, 1996
36. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56:689-693, 1996
37. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75:230-235, 1997
38. Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini S, Pepe S, Macchiarini P, Chella A, Angeletti CA, Callahan R, Bistocchi M, Squartini F: p53 alterations in non-small-cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53:2846-2851, 1993
39. Bosari S, Lee KC, Viale G, Heatley GJ, Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Archiv A Pathol Anat 421:291-295, 1992
40. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Doge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51:2979-2984, 1991
41. Kohler MF, Kerns BJM, Humphrey PA, Marks JR, Bast RC, Jr, Berchuck A: Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81:643-650, 1993
42. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G: p53 accumulation in ovarian carcinomas and its prognostic implication. Human Pathol 24:1175-1179, 1993
43. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327-1338, 1995
44. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56:2178-2184, 1996
45. Winter SF, Sekido Y, Minna JD, McIntire D, Johnsons BE, Gazdar AF, Carbone DP: Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 85:2012-2018, 1993